Core Viewpoint - Huadong Medicine has entered into a strategic partnership with MC2 Therapeutics to commercialize the Biomee skincare series in Greater China, enhancing their collaboration following the successful introduction of the Wynzora ointment for psoriasis treatment [1][2]. Group 1: Partnership and Product Development - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has secured exclusive commercialization rights for the Biomee series in Greater China [1]. - The partnership builds on previous successful collaborations, particularly the introduction of the Wynzora ointment, and aims to expand into the dermatological market [2][3]. - A Phase III clinical trial for the MC2-01 ointment, which combines calcipotriol and betamethasone, has commenced, marking a significant milestone in product development [1][3]. Group 2: Market Potential and Product Features - The Biomee series, developed using MC2's PAD technology, addresses common skin issues such as dryness and discomfort, with a focus on providing effective and safe relief [2][3]. - The Chinese dermatological skincare market has shown rapid growth, increasing from 8.52 billion yuan in 2017 to 31.17 billion yuan in 2023, with projections to reach 65 billion yuan by 2028 [3]. - The Biomee series targets widespread skin concerns, making it appealing across various age groups and enhancing market potential [3]. Group 3: Strategic Positioning and Future Outlook - The introduction of the Biomee series is part of Huadong Medicine's comprehensive strategy in the dermatological sector, combining partnerships and in-house development [5][6]. - The company has established a leading product portfolio in the psoriasis treatment space, including biologics and topical prescription drugs, ensuring comprehensive patient care [5]. - Huadong Medicine's collaboration with MC2 on the Biomee series signifies a strategic advancement in the skin health sector, aiming to meet the growing and diverse demands for skin health solutions in Greater China [6].

Core Viewpoint - Huadong Medicine's subsidiary, Zhejiang Zhongmei Huadong Pharmaceutical, received approval for a Phase III clinical trial of 0.3% roflumilast foam (ZORYVE) for seborrheic dermatitis patients, indicating a significant advancement in treatment options for this condition [1][2]. Group 1: Product Development and Clinical Trials - The approved clinical trial targets local treatment for patients aged 9 and above with seborrheic dermatitis, utilizing roflumilast, a PDE4 inhibitor that reduces inflammation [2]. - Roflumilast foam has shown significant efficacy, with nearly 80% of patients achieving complete or near-complete clearance of symptoms by week 8, while maintaining good safety and tolerability [2]. - The product is designed for ease of use, with a once-daily application and no long-term usage restrictions compared to traditional topical corticosteroids [2]. Group 2: Market Potential and Demand - There is a substantial unmet clinical need for effective treatments for seborrheic dermatitis, as existing therapies often have limited efficacy and significant side effects [2]. - The Chinese psoriasis drug market is projected to reach $3.255 billion by 2025, while the global atopic dermatitis treatment market is expected to reach $24.5 billion by 2032, highlighting the market potential for roflumilast [4]. Group 3: Company Strategy and Innovation - Huadong Medicine is focusing on autoimmune diseases, with a comprehensive pipeline that includes over 20 innovative products targeting various conditions, including psoriasis and atopic dermatitis [5]. - The company has established an R&D platform for topical formulations and has built three production lines for external preparations, indicating a strong commitment to innovation in this area [8]. - Huadong Medicine aims to enhance the accessibility of innovative drugs and provide differentiated treatment options, positioning itself for long-term competitive advantage in the autoimmune sector [9].